PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Cited by (1,079)

Items 101–200 of 1,079

1. Immune checkpoint therapy—current perspectives and future directions
   Sharma, Padmanee, Goswami, Sangeeta, Raychaudhuri, Deblina, Siddiqui, Bilal A., Singh, Pratishtha, Nagarajan, Ashwat, Liu, Jielin, Subudhi, Sumit K., Poon, Candice, Gant, Kristal L. et al. · 2023 · Cell
2. State-of-the-art strategies for targeting the DNA damage response in cancer
   Pilié, Patrick G., Tang, Chad, Mills, Gordon B., Yap, Timothy A. · 2019 · Nature Reviews Clinical Oncology
3. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
   Raju Kumar Vaddepally, Prakash Kharel, Ramesh Kumar Pandey, Rohan Garje, Abhinav Binod Chandra · 2020 · Cancers
4. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
   Marcus, Leigh, Lemery, Steven J., Keegan, Patricia, Pazdur, Richard · 2019 · Clinical Cancer Research
5. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
   Chowell, Diego, Morris, Luc G. T., Grigg, Claud M., Weber, Jeffrey K., Samstein, Robert M., Makarov, Vladimir, Kuo, Fengshen, Kendall, Sviatoslav M., Requena, David, Riaz, Nadeem et al. · 2018 · Science
6. Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids
   Dijkstra, Krijn K., Cattaneo, Chiara M., Weeber, Fleur, Chalabi, Myriam, van de Haar, Joris, Fanchi, Lorenzo F., Slagter, Maarten, van der Velden, Daphne L., Kaing, Sovann, Kelderman, Sander et al. · 2018 · Cell
7. RAS-targeted therapies: is the undruggable drugged?
   Moore, Amanda R., Rosenberg, Scott C., McCormick, Frank, Malek, Shiva · 2020 · Nature Reviews Drug Discovery
8. Biliary tract cancer
   Juan W. Valle, Robin Kate Kelley, Bruno Nervi, Do‐Youn Oh, Andrew Xiuxuan Zhu · 2021 · The Lancet
9. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer.
   Arbour, Kathryn C., Mezquita, Laura, Long, Niamh, Rizvi, Hira, Auclin, Edouard, Ni, Andy, Martínez-Bernal, Gala, Ferrara, Roberto, Lai, W. Victoria, Hendriks, Lizza E.L. et al. · 2018 · Journal of Clinical Oncology
10. Towards personalized, tumour-specific, therapeutic vaccines for cancer
    Hu, Zhuting, Ott, Patrick A., Wu, Catherine J. · 2018 · Nature Reviews Immunology
11. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
    Jaffer A. Ajani, Thomas Anthony D’Amico, David J. Bentrem, Joseph Chao, Carlos Uriel Corvera, Prajnan Das, Crystal Shereen Denlinger, Peter C. Enzinger, Paul Timothy Fanta, Farhood Farjah et al. · 2019 · Journal of the National Comprehensive Cancer Network
12. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
    Claudio Luchini, Frédéric Bibeau, M.J.L. Ligtenberg, Naveena Singh, Alessia Nottegar, Tjalling Bosse, Rowan E. Miller, Nadeem Riaz, J-Y Douillard, Fabrice André et al. · 2019 · Annals of Oncology
13. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
    Blass, Eryn, Ott, Patrick A. · 2021 · Nature Reviews Clinical Oncology
14. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
    Jonathan M. Pitt, Marie Vétizou, Romain Daillère, María Paula Roberti, Takahiro Yamazaki, Bertrand Routy, Patricia Lepage, Ivo Gomperts Boneca, Mathias Chamaillard, Guido Kroemer et al. · 2016 · Immunity
15. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
    Rodrigo Dienstmann, Louis Vermeulen, Justin Guinney, Scott Kopetz, Sabine Tejpar, Josep M. Tabernero · 2017 · Nature reviews. Cancer
16. Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
    Mlecnik, Bernhard, Bindea, Gabriela, Angell, Helen K., Maby, Pauline, Angelova, Mihaela, Tougeron, David, Church, Sarah E., Lafontaine, Lucie, Fischer, Maria, Fredriksen, Tessa et al. · 2016 · Immunity
17. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
    Daniel James McGrail, P.G. Pilié, N.U. Rashid, Leonie Voorwerk, Maarten Slagter, Marleen Kok, Eric W. Jonasch, Mustafa Khasraw, A.B. Heimberger, Bora Lim et al. · 2021 · Annals of Oncology
18. Monitoring immune-checkpoint blockade: response evaluation and biomarker development
    Nishino, Mizuki, Ramaiya, Nikhil H., Hatabu, Hiroto, Hodi, F. Stephen · 2017 · Nature Reviews Clinical Oncology
19. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164
    Le, Dung T., Kim, Tae Won, Van Cutsem, Eric, Geva, Ravit, Jäger, Dirk, Hara, Hiroki, Burge, Matthew, O’Neil, Bert, Kavan, Petr, Yoshino, Takayuki et al. · 2020 · Journal of Clinical Oncology
20. The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
    Hegde, Priti S., Karanikas, Vaios, Evers, Stefan · 2016 · Clinical Cancer Research
21. Targeting neoantigens to augment antitumour immunity
    Yarchoan, Mark, Johnson, Burles A., Lutz, Eric R., Laheru, Daniel A., Jaffee, Elizabeth M. · 2017 · Nature Reviews Cancer
22. Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer
    Aline Talhouk, Melissa K. McConechy, Samuel C. Y. Leung, Winnie Yang, Amy M. Lum, Janine Senz, Niki Boyd, J.A. Pike, Michael S. Anglesio, Janice S. Kwon et al. · 2017 · Cancer
23. NCCN Guidelines Insights: Colon Cancer, Version 2.2018
    Al B. Benson, Alan Paul Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi‐Jen Chen, Kristen Keon Ciombor, Stacey A. Cohen, Harry S. Cooper, Dustin A. Deming, Paul F. Engstrom et al. · 2018 · Journal of the National Comprehensive Cancer Network
24. Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures
    Zeng, Dongqiang, Li, Meiyi, Zhou, Rui, Zhang, Jingwen, Sun, Huiying, Shi, Min, Bin, Jianping, Liao, Yulin, Rao, Jinjun, Liao, Wangjun · 2019 · Cancer Immunology Research
25. Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and SPP1+ macrophages in colorectal cancer
    Jingjing Qi, Hongxiang Sun, Yao Zhang, Zhengting Wang, Zhenzhen Xun, Ziyi Li, Xinyu Ding, Rujuan Bao, Liwen Hong, Wenqing Jia et al. · 2022 · Nature Communications
26. Classification and characterization of microsatellite instability across 18 cancer types
    Ronald J. Hause, Colin C. Pritchard, Jay Shendure, Stephen J. Salipante · 2016 · Nature Medicine
27. The rediscovery of platinum-based cancer therapy
    Sven Rottenberg, Carmen Disler, Paola Perego · 2020 · Nature reviews. Cancer
28. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
    Sia, Daniela, Jiao, Yang, Martinez-Quetglas, Iris, Kuchuk, Olga, Villacorta-Martin, Carlos, Castro de Moura, Manuel, Putra, Juan, Camprecios, Genis, Bassaganyas, Laia, Akers, Nicholas et al. · 2017 · Gastroenterology
29. T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
    Ott, Patrick A., Bang, Yung-Jue, Piha-Paul, Sarina A., Razak, Albiruni R. Abdul, Bennouna, Jaafar, Soria, Jean-Charles, Rugo, Hope S., Cohen, Roger B., O’Neil, Bert H., Mehnert, Janice M. et al. · 2019 · Journal of Clinical Oncology
30. Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
    Dong, Zhong-Yi, Zhong, Wen-Zhao, Zhang, Xu-Chao, Su, Jian, Xie, Zhi, Liu, Si-Yang, Tu, Hai-Yan, Chen, Hua-Jun, Sun, Yue-Li, Zhou, Qing et al. · 2017 · Clinical Cancer Research
31. Pancreatic cancer stroma: an update on therapeutic targeting strategies
    Hosein, Abdel N., Brekken, Rolf A., Maitra, Anirban · 2020 · Nature Reviews Gastroenterology &amp; Hepatology
32. Combination cancer immunotherapies tailored to the tumour microenvironment
    Smyth, Mark J., Ngiow, Shin Foong, Ribas, Antoni, Teng, Michele W. L. · 2016 · Nature Reviews Clinical Oncology
33. Molecular profiling for precision cancer therapies
    Eoghan Ruadh Malone, Marc Oliva, Peter J. B. Sabatini, Tracy L. Stockley, Lillian L. Siu · 2020 · Genome Medicine
34. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
    Duhen, Thomas, Duhen, Rebekka, Montler, Ryan, Moses, Jake, Moudgil, Tarsem, de Miranda, Noel F., Goodall, Cheri P., Blair, Tiffany C., Fox, Bernard A., McDermott, Jason E. et al. · 2018 · Nature Communications
35. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
    Leila Khoja, Daphne Day, Tom Wei‐Wu Chen, Lilian L. Siu, Aaron Richard Hansen · 2017 · Annals of Oncology
36. Microsatellite Instability as a Biomarker for PD-1 Blockade
    Jonathan C. Dudley, Ming‐Tseh Lin, Dung Thi Le, James R. Eshleman · 2016 · Clinical Cancer Research
37. The Dualistic Model of Ovarian Carcinogenesis
    Robert J. Kurman, Ie‐Ming Shih · 2016 · American Journal Of Pathology
38. Current Challenges in Cancer Treatment
    Jon Zugazagoitia, Cristiano Guedes, Santiago Ponce, Irene Ferrer, Sonia Molina‐Pinelo, Luis G Paz-Ares · 2016 · Clinical Therapeutics
39. β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
    Ruiz de Galarreta, Marina, Bresnahan, Erin, Molina-Sánchez, Pedro, Lindblad, Katherine E., Maier, Barbara, Sia, Daniela, Puigvehi, Marc, Miguela, Verónica, Casanova-Acebes, María, Dhainaut, Maxime et al. · 2019 · Cancer Discovery
40. Coinhibitory Pathways in Immunotherapy for Cancer
    Susanne H.C. Baumeister, Gordon James Freeman, Glenn Dranoff, Arlene H. Sharpe · 2016 · Annual Review of Immunology
41. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
    Marios Giannakis, Xinmeng Jasmine Mu, Sachet Ashok Shukla, Zhi Rong Qian, Ofir Cohen, Reiko Nishihara, Samira Bahl, Yin Cao, Ali Amin‐Mansour, Mai Yamauchi et al. · 2016 · Cell Reports
42. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
    Samra Turajlic, Kevin Litchfield, Hang Xu, Rachel Rosenthal, Nicholas McGranahan, James L. Reading, Yien Ning Sophia Wong, Andrew Rowan, Nnennaya Kanu, Maise Al Bakir et al. · 2017 · The Lancet Oncology
43. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
    Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., Cauquil, C., Chanson, P., Collins, M., Durrbach, A. et al. · 2016 · Annals of Oncology
44. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
    Zhao, Junfei, Chen, Andrew X., Gartrell, Robyn D., Silverman, Andrew M., Aparicio, Luis, Chu, Tim, Bordbar, Darius, Shan, David, Samanamud, Jorge, Mahajan, Aayushi et al. · 2019 · Nature Medicine
45. Spatially organized multicellular immune hubs in human colorectal cancer
    Karin Pelka, Matan Hofree, Jonathan H. Chen, Siranush Sarkizova, Joshua D. Pirl, Vjola Jorgji, Alborz Bejnood, Danielle Ashley Dionne, William H. Ge, Katherine H. Xu et al. · 2021 · Cell
46. Dendritic Cells and Cancer Immunity
    Alycia Gardner, Brian Ruffell · 2016 · Trends in Immunology
47. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
    Litchfield, Kevin, Reading, James L., Puttick, Clare, Thakkar, Krupa, Abbosh, Chris, Bentham, Robert, Watkins, Thomas B.K., Rosenthal, Rachel, Biswas, Dhruva, Rowan, Andrew et al. · 2021 · Cell
48. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
    Yucai Wang, Shouhao Zhou, Fang Yang, Xinyue Qi, Xin Wang, Xiaoxiang Guan, Chan Shen, Narjust Duma, Jesus Vera Aguilera, Ashish Vittalrao Chintakuntlawar et al. · 2019 · JAMA Oncology
49. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
    Roh, Whijae, Chen, Pei-Ling, Reuben, Alexandre, Spencer, Christine N., Prieto, Peter A., Miller, John P., Gopalakrishnan, Vancheswaran, Wang, Feng, Cooper, Zachary A., Reddy, Sangeetha M. et al. · 2017 · Science Translational Medicine
50. Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors
    Sha, Dan, Jin, Zhaohui, Budczies, Jan, Kluck, Klaus, Stenzinger, Albrecht, Sinicrope, Frank A. · 2020 · Cancer Discovery
51. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
    Laura Q.M. Chow, Robert I. Haddad, Shilpa Gupta, Amit Mahipal, Ranee Mehra, Makoto Tahara, Raanan Berger, Joseph P. Eder, Barbara Ann Burtness, Se‐Hoon Lee et al. · 2016 · Journal of Clinical Oncology
52. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency
    Bouffet, Eric, Larouche, Valérie, Campbell, Brittany B., Merico, Daniele, de Borja, Richard, Aronson, Melyssa, Durno, Carol, Krueger, Joerg, Cabric, Vanja, Ramaswamy, Vijay et al. · 2016 · Journal of Clinical Oncology
53. Management of toxicities of immune checkpoint inhibitors
    Spain, Lavinia, Diem, Stefan, Larkin, James · 2016 · Cancer Treatment Reviews
54. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
    Joaquı́n Mateo, Debyani Chakravarty, Rodrigo Dienstmann, S. Jezdic, Abel González-Pérez, Núria López-Bigas, Charlotte K.Y. Ng, Philippe Lucien Bedard, Giampaolo Tortora, J.-Y. Douillard et al. · 2018 · Annals of Oncology
55. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
    2017
56. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
    Alena Gros, Maria R. Parkhurst, Eric Tran, Anna Pasetto, Paul F. Robbins, Sadia Ilyas, Todd D. Prickett, Jared J. Gartner, Jessica S. Crystal, Ilana M. Roberts et al. · 2016 · Nature Medicine
57. Tumour evolution in hepatocellular carcinoma
    Amanda J. Craig, Johann von Felden, Teresa García‐Lezana, Samantha Sarcognato, Augusto Villanueva · 2019 · Nature Reviews Gastroenterology & Hepatology
58. Intratumoral heterogeneity in cancer progression and response to immunotherapy
    Ilio Vitale, Efrat Shema, Sherene Loi, Lorenzo Galluzzi · 2021 · Nature Medicine
59. Epigenetics of colorectal cancer: biomarker and therapeutic potential
    Jung, Gerhard, Hernández-Illán, Eva, Moreira, Leticia, Balaguer, Francesc, Goel, Ajay · 2020 · Nature Reviews Gastroenterology &amp; Hepatology
60. Glioma Subclassifications and Their Clinical Significance
    Chen, Ricky, Smith-Cohn, Matthew, Cohen, Adam L., Colman, Howard · 2017 · Neurotherapeutics
61. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
    Shona A. Hendry, Roberto Salgado, Thomas Gevaert, Prudence Anne Russell, Tom John, Bibhusal Thapa, Michael Christie, Koen K Van de Vijver, Monica Valeria Estrada, Paula I. González Ericsson et al. · 2017 · Advances in Anatomic Pathology
62. Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities
    Vasaikar, Suhas, Huang, Chen, Wang, Xiaojing, Petyuk, Vladislav A., Savage, Sara R., Wen, Bo, Dou, Yongchao, Zhang, Yun, Shi, Zhiao, Arshad, Osama A. et al. · 2019 · Cell
63. The inflammatory pathogenesis of colorectal cancer
    Mark Schmitt, Florian R. Greten · 2021 · Nature reviews. Immunology
64. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
    Pedram Razavi, Bob T. Li, David N. Brown, Byoungsok Jung, Earl A. Hubbell, Ronglai Shen, Wassim M. Abida, Krishna Juluru, Ino de Bruijn, Chenlu Hou et al. · 2019 · Nature Medicine
65. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
    Ramez Nassef Eskander, Michael W. Sill, Lindsey B. Beffa, Richard G. Moore, Joanie Mayer Hope, Fernanda Musa, Robert S. Mannel, Mark S. Shahin, Guilherme Henrique Cantuaria, Eugenia Girda et al. · 2023 · New England Journal of Medicine
66. PD-L1 expression in human cancers and its association with clinical outcomes
    Yu, Jinming, Wang, Xin, Teng, Feifei, Kong, Li · 2016 · OncoTargets and Therapy
67. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group
    Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J.D., Montagut, C. et al. · 2022 · Annals of Oncology
68. Review of precision cancer medicine: Evolution of the treatment paradigm
    Apostolia Maria Tsimberidou, Elena Fountzilas, Mina Nikanjam, Razelle Kurzrock · 2020 · Cancer Treatment Reviews
69. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial
    O’Reilly, Eileen M., Oh, Do-Youn, Dhani, Neesha, Renouf, Daniel J., Lee, Myung Ah, Sun, Weijing, Fisher, George, Hezel, Aram, Chang, Shao-Chun, Vlahovic, Gordana et al. · 2019 · JAMA Oncology
70. The head and neck cancer immune landscape and its immunotherapeutic implications
    Rajarsi Mandal, Yasin Şenbabaoğlu, Alexis Desrichard, Jonathan J. Havel, Martin G. Dalin, Nadeem Riaz, Ken-Wing Lee, Ian Ganly, A. Ari Hakimi, Timothy An-thy Chan et al. · 2016 · JCI Insight
71. Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer
    Mizuki Nishino, Anita Giobbie‐Hurder, Hiroto Hatabu, Nikhil H. Ramaiya, Frank Stephen Hodi · 2016 · JAMA Oncology
72. Comprehensive Analysis of Hypermutation in Human Cancer
    Brittany B. Campbell, Nicholas D Light, David A. Fabrizio, Matthew Zatzman, Fabio Fuligni, Richard de Borja, Scott Davidson, Melissa Edwards, Julia Andrea Elvin, Karl P. Hodel et al. · 2017 · Cell
73. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy
    Chunbai He, Xiaopin Duan, Nining Guo, Christina Chan, Christopher J. Poon, Ralph R. Weichselbaum, Wenbin Lin · 2016 · Nature Communications
74. Gut microbiota in colorectal cancer development and therapy
    Chi Chun Wong, Jun Yu · 2023 · Nature Reviews Clinical Oncology
75. The Next Decade of Immune Checkpoint Therapy
    Sharma, Padmanee, Siddiqui, Bilal A., Anandhan, Swetha, Yadav, Shalini S., Subudhi, Sumit K., Gao, Jianjun, Goswami, Sangeeta, Allison, James P. · 2021 · Cancer Discovery
76. The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
    Alireza Labani‐Motlagh, Mehrnoush Ashja-Mahdavi, Angelica Loskog · 2020 · Frontiers in Immunology
77. The “cancer immunogram”
    Blank, Christian U., Haanen, John B., Ribas, Antoni, Schumacher, Ton N. · 2016 · Science
78. The clinical role of the TME in solid cancer
    Nicolás A. Giraldo, Rafael Sánchez-Salas, J. David Peske, Yann Alexandre Vano, Étienne Becht, Florent Petitprez, Pierre Validire, Alexandre Ingels, Xavier Cathelineau, Wolf H. Fridman et al. · 2018 · British Journal of Cancer
79. Immunogenicity of somatic mutations in human gastrointestinal cancers
    Tran, Eric, Ahmadzadeh, Mojgan, Lu, Yong-Chen, Gros, Alena, Turcotte, Simon, Robbins, Paul F., Gartner, Jared J., Zheng, Zhili, Li, Yong F., Ray, Satyajit et al. · 2015 · Science
80. Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer
    Rachel Pearlman, Wendy L. Frankel, Benjamin J. Swanson, Weiqiang Zhao, Ahmet Uğur Yılmaz, Kristin Miller, Jason Bacher, Christopher J. Bigley, Lori Nelsen, Paul J. Goodfellow et al. · 2016 · JAMA Oncology
81. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
    Ezra E.W. Cohen, R. Bryan Bell, Carlo Bruno Bifulco, Barbara Ann Burtness, Maura L. Gillison, Kevin Joseph Harrington, Quynh‐Thu Le, Nancy Y. Lee, Rom S. Leidner, Rebecca L. Lewis et al. · 2019 · Journal for ImmunoTherapy of Cancer
82. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
    Jason Keith Sicklick, Shumei Kato, Ryosuke Okamura, Maria Clemence Schwaederle, Michael E. Hahn, Casey B. Williams, Pradip K. De, Amy K. Krie, David Eric Piccioni, Vincent A. Miller et al. · 2019 · Nature Medicine
83. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
    Hiro Sato, Atsuko Niimi, Takaaki Yasuhara, Tiara Bunga Mayang Permata, Yoshihiko Hagiwara, Mayu Isono, Endang Nuryadi, Ryota Sekine, Takahiro Oike, Sangeeta Kakoti et al. · 2017 · Nature Communications
84. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials
    Tejpar, Sabine, Stintzing, Sebastian, Ciardiello, Fortunato, Tabernero, Josep, Van Cutsem, Eric, Beier, Frank, Esser, Regina, Lenz, Heinz-Josef, Heinemann, Volker · 2017 · JAMA Oncology
85. Vaccines for established cancer: overcoming the challenges posed by immune evasion
    Sjoerd H. van der Burg, Ramon Arens, FERRY A. OSSENDORP, Thorbald van Hall, Cornelis J.M. Melief · 2016 · Nature reviews. Cancer
86. Endometrial cancer
    Vicky Makker, Helen J MacKay, Isabelle Laure Ray-Coquard, Douglas A. Levine, Shannon Neville Westin, Daisuke Aoki, Ana Oaknin · 2021 · Nature Reviews Disease Primers
87. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
    Mezzadra, Riccardo, Sun, Chong, Jae, Lucas T., Gomez-Eerland, Raquel, de Vries, Evert, Wu, Wei, Logtenberg, Meike E. W., Slagter, Maarten, Rozeman, Elisa A., Hofland, Ingrid et al. · 2017 · Nature
88. Metastatic colorectal cancer: mechanisms and emerging therapeutics
    Alice E. Shin, Filippo G. Giancotti, Anil K. Rustgi · 2023 · Trends in Pharmacological Sciences
89. Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells
    De Simone, Marco, Arrigoni, Alberto, Rossetti, Grazisa, Gruarin, Paola, Ranzani, Valeria, Politano, Claudia, Bonnal, Raoul J.P., Provasi, Elena, Sarnicola, Maria Lucia, Panzeri, Ilaria et al. · 2016 · Immunity
90. RNA splicing factors as oncoproteins and tumour suppressors
    Heidi Dvinge, Eun Hee Kim, Omar Ibrahim Abdel-Wahab, Robert K. Bradley · 2016 · Nature reviews. Cancer
91. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
    Zhao, Pengfei, Li, Li, Jiang, Xiaoyue, Li, Qin · 2019 · Journal of Hematology &amp; Oncology
92. Ionic immune suppression within the tumour microenvironment limits T cell effector function
    Robert L Eil, Suman Kumar Vodnala, David C. Clever, Christopher Austin Klebanoff, Madhusudhanan Sukumar, Jenny H. Pan, Douglas C. Palmer, Alena Gros, Tori N. Yamamoto, Shashank J. Patel et al. · 2016 · Nature
93. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment
    Muyue Yang, Jipeng Li, Ping Gu, Xianqun Fan · 2020 · Bioactive Materials
94. Challenges and Opportunities for Pancreatic Cancer Immunotherapy
    Bear, Adham S., Vonderheide, Robert H., O'Hara, Mark H. · 2020 · Cancer Cell
95. Mechanisms and therapeutic implications of hypermutation in gliomas
    Mehdi Touat, Yvonne Y. Li, Adam N. Boynton, Liam Flinn Spurr, Julian Bryan Iorgulescu, Craig L. Bohrson, Isidro Cortés‐Ciriano, Cristina Birzu, Jack E. Geduldig, Kristine Pelton et al. · 2020 · Nature
96. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
    Chan-Seng-Yue, Michelle, Kim, Jaeseung C., Wilson, Gavin W., Ng, Karen, Figueroa, Eugenia Flores, O’Kane, Grainne M., Connor, Ashton A., Denroche, Robert E., Grant, Robert C., McLeod, Jessica et al. · 2020 · Nature Genetics
97. Impact of oncogenic pathways on evasion of antitumour immune responses
    Stefani Spranger, Thomas Frank Gajewski · 2018 · Nature reviews. Cancer
98. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
    Kabir A. Khan, Robert S. Kerbel · 2018 · Nature Reviews Clinical Oncology
99. Pan-cancer image-based detection of clinically actionable genetic alterations
    Jakob Nikolas Kather, Lara Rosaline Heij, Heike Irmgard Grabsch, Chiara Maria Lavinia Loeffler, Amelie Echle, Hannah Sophie Muti, Jeremias Krause, Jan Niehues, Kai A. J. Sommer, Peter Bankhead et al. · 2020 · Nature Cancer
100. From tumour heterogeneity to advances in precision treatment of colorectal cancer
     Punt, Cornelis J. A., Koopman, Miriam, Vermeulen, Louis · 2017 · Nature Reviews Clinical Oncology